This decade, a lot of clinical trials regarding CAR-T therapy were carried out around the world. As of April 19, 2018, the information from Clinicaltrails.gov showed that more than 270 CAR T-related studies were undergoing clinical trials in many different countries.
By analyzing the overall response rate (ORR) and complete response rate (CRR) of CAR T therapy in patients with different tumors, we found that the response rate was significantly higher for patients with hematologic malignancies compared to patients with solid malignancies.
New research & update on pivotal trials
“Ref: Am J Hematol. 2018;93:851–858”
Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia
A total of 18 R/R ALL patients with or without prior murine CD19 CAR-T therapy were treated with humanized CD19-targeted CAR-T cells (hCART19s).
13 out of 14 patients without previous CAR-T therapy achieved complete remission (CR) or CR with incomplete count recovery (CRi) on day 30.
At day 180, the overall and leukemia-free survival rates were 65.8% and 71.4%, respectively.
“Ref: IACH2018, CART Poster, Sept 2018”
Real World Experience in Using CD19 CAR-T Therapy for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) in Malaysia
A total of 10 patients with critically ill relapsed/refractory (r/r) B-ALL were referred from various hospitals in Malaysia & treated for CAR-T therapy on compassionate use basis approved by the Ministry of Health (MOH) Malaysia.
“Ref: Lancet Haematol 2019, http://dx.doi.org/10.1016/S2352-3026(19)30115-2”
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
single-centre, single-arm, phase 2 trial at the Affiliated Hospital of Xuzhou Medical University in China. Aged 18–69 years, had histologically confirmed multiple myeloma, and met the International Myeloma Working Group diagnostic criteria for relapsed or refractory disease
This dual CAR-T cell combinations might be a promising treatment option for relapsed or refractory multiple myeloma
Our T-cell-based immunotherapies have shown compelling clinical results across S.E. Asia and academic clinical trials with strong evidence in:
Clinical Proven Efficacy
Safety Profile
Persistence